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As summarized in the first article in this continuing medical education series, the currently available
epidemiologic data suggest that psoriasis may be a risk factor for cardiometabolic disease. Emerging data also
suggest associations between psoriasis and other comorbidities beyond psoriatic arthritis, including chronic
kidney disease, inflammatory bowel disease, hepatic disease, certain malignancies, infections, and mood
disorders. Recognizing the comorbid disease burden of psoriasis is essential for ensuring comprehensive care of
patients with psoriasis. The clinical implications of the comorbid diseases that are associated with psoriasis and
recommendations for clinical management are reviewed in this article. ( J Am Acad Dermatol 2017;76:393-403.)
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Learning objectives
After completing this learning activity, participants should be able to determine psoriasis treatment options for patients who also have significant cardiovascular risk factors, such as
obesity and/or diabetes; provide appropriate screening for psoriasis patients according to recommended guidelines; and identify optimal treatment regimens for patients with
moderate to severe psoriasis and associated cardiovascular, infectious, or rheumatologic comorbidities.
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CARDIOMETABOLIC DISEASE
Key points
d Patients with psoriasis are underscreened
and undertreated for cardiovascular risk
factors
d At a minimum, patients with psoriasis
should be screened for cardiovascular risk
factors according to recommendations for
the general adult population
d Observational data suggest that treatment
with methotrexate or tumor necrosis factor
inhibitors is associated with a decrease in
cardiovascular events; however, data from
randomized controlled trials are not yet
available, and data for other psoriasis ther-
apies are lacking
In spite of the evidence supporting an increased
prevalence of cardiovascular (CV) risk factors and
increased risks of CV disease (CVD) and mortality
among patients with psoriasis, data suggest that
patients are inadequately screened and undertreated
for CV risk factors.1-5 For example, in a cross-
sectional study of National Ambulatory Medical
Care Survey data from 2005 to 2009, only 41% of
patients with psoriasis versus 66% of those without
psoriasis were screened for $1 CV risk factor (ie,
blood pressure, glucose, cholesterol, or body mass
index [BMI]).4 Specifically among dermatologists,
screening for CV risk factors was infrequent (blood
pressure, 2.6%; glucose, 1.2%; cholesterol, 4.3%; and
BMI, 9.7%). Similarly, a 2015 survey of 127 US
dermatologists revealed that \50% screened for
hypertension, dyslipidemia, or diabetes in patients
with psoriasis.5 In addition, in a cross-sectional study
of patients with hypertension in the United
Kingdom, patients with psoriasis were more likely
to have uncontrolled hypertension compared with
patients without psoriasis.3 Together, these data
highlight an important health care systems gap in
screening for and treating CV risk factors among
patients with psoriasis. Therefore, as recommended
by clinical practice guidelines,6,7 dermatologists
should, at a minimum, advise patients with moderate
to severe psoriasis of their possible increased risk of
CVD and recommend that they see their primary care
physician for appropriate medical screenings and
assessment.
Major adverse cardiovascular events
Screening for CV risk factors among patients with
psoriasis, particularly those with more severe
disease, is essential to minimizing risk of major
adverse cardiovascular events (MACE). Screening
and management of CV risk factors in patients with
psoriasis should, at a minimum, follow recommen-
dations for the general adult population (level of
evidence, IB).6-8 In addition, lifestyle interventions,
such as weight loss and smoking cessation, should
be encouraged among psoriasis patients who are
obese and who are current smokers, respectively
(level of evidence, IB). According to the American
College of Cardiology and American Heart
Association guidelines, CV risk assessment should
include evaluation of traditional risk factors every 4
to 6 years among persons 20 to 79 years of age and
estimation of 10-year CVD risk among those 40 to
79 years of age (Table I).9
Important questions that remain unanswered
include what the particular CV risk factor treatment
goals should be for psoriasis patients and whether
the presence of psoriasis alone warrants different or
more aggressive screening and management strate-
gies for CV risk factors compared with the general
population. Mehta et al’s study10 of the impact of
psoriasis on the Framingham Risk Score found that
the addition of psoriasis warranted a change in CV
risk factor treatment plans and goals for [60% of
patients.10 Therefore, psoriasis itselfdespecially
severe diseasedmay indeed necessitate clinically
significant changes in prevention and treatment
goals for CV risk factors in a similar manner to what
has been recommended by the European League
Against Rheumatism for patients with rheumatoid
arthritis (RA).11
Critically, it remains unknown if successful treat-
ment of psoriasis will lower the risk of future CV
events. The treatment of psoriasis is currently
Abbreviations used:
BMI: body mass index
BSA: body surface area
CD: Crohn’s disease
CDC: Centers for Disease Control and
Prevention
CIRT: Cardiovascular Inflammation Reduction
Trial
CTCL: cutaneous T-cell lymphoma
CV: cardiovascular
CVD: cardiovascular disease
FDA: US Food and Drug Administration
IBD: inflammatory bowel disease
IL: interleukin
MACE: major adverse cardiovascular events
NAFLD: nonalcoholic fatty liver disease
NMSC: nonmelanoma skin cancer
PASI: Psoriasis Area and Severity Index
PUVA: psoralen plus ultraviolet A light
phototherapy
RA: rheumatoid arthritis
RCT: randomized controlled trial
TB: tuberculosis
TNF: tumor necrosis factor
UC: ulcerative colitis
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considered to be elective, and systemic treatments
are reserved for patients with severe disease that is
physically or psychologically disabling to the patient.
As a result, the overwhelming majority of patients,
even with objectively severe psoriasis, do not receive
adequate treatment to control their skin disease.12-14
This view of psoriasis may be similar to that of
hypertension in the 1960s when treatment was
considered elective and potentially harmful in the
elderly until randomized controlled trials (RCTs)
showed improved CV outcomes and decreased
mortality among those receiving antihypertensive
therapy.15,16 Unlike hypertension, there are currently
no RCTs to prove that psoriasis therapies lower the
risk of CVD. Meta-analyses of observational studies
suggest that methotrexate and tumor necrosis factor
(TNF) inhibitors may lower the risk of CV events in
patients with RA.17-19 Similarly, emerging data from
observational studies of psoriasis suggest that meth-
otrexate and TNF inhibitors may lower the risk of CV
events in patients with psoriasis20-22; however not all
studies have observed a protective effect,23,24 and
the observational nature of the studies limits the
conclusions that can be drawn. Mixed results from
studies of psoriasis therapy effects on the risk of CV
events, which have also been observed in the RA
population, may be related to differences in study
design, uses of different comparator groups, and
misclassification of treatment status, and they
highlight the need for RCTs to better address this
question.25 Therefore, RCTs evaluating the effects of
psoriasis therapy on CVD using rigorous surrogate
markers, such as vascular inflammation26,27 and,
ultimately, on CV events are essential. Initial
studies in RA28 and psoriasis29 suggest that TNF
inhibitors may reduce vascular inflammation as
measured by 18-fluorodeoxyglucose positron
emission tomography-computed tomography.
Multiple studies are ongoing to evaluate the
effects of ultraviolet B phototherapy (ClinicalTrials.
gov identifier NCT01553058), TNF inhibition
(NCT01553058, 01866592), interleukin (IL) 12/23
inhibition (NCT02187172), and IL-17 inhibition
(NCT02690701) on vascular inflammation. Finally,
underscoring the importance of testing the inflam-
matory hypothesis in CVD, the Cardiovascular
Inflammation Reduction Trial (CIRT; NCT01594333)
is an ongoing RCT studying the effect of metho-
trexate on the incidence of MACE in patients with
type 2 diabetes or metabolic syndrome who have
had a previous MI.30 The CIRT trial is not a study of
patients with psoriasis, but it will be important in
establishing whether methotrexate treatment of
inflammation reduces the residual risk of CVD. If
these or other future RCTs reveal a protective effect
of psoriasis treatments on CVD, a paradigm shift in
the current view of psoriasis therapy will be needed,
and support for a causal relationship between pso-
riasis and CVD would be strengthened.
Obesity
Obesity may have important effects on psoriasis
severity and response to therapies. The impact of
weight loss interventions (either diet modification or
exercise) on psoriasis severity was assessed in a
systematic review and meta-analysis of 7 RCTs of 878
participants.31 The meta-analysis of 3 RCTs found a
significantly greater reduction in the Psoriasis Area
and Severity Index (PASI) score among patients
receiving the weight loss intervention than those
who did not receive the intervention (pooled mean
PASI difference,22.49 [95% confidence interval {CI},
23.90 to 21.08). Similarly, among 4 studies that
assessed 75% reduction in the PASI score (PASI-75) as
an outcome, more participants in the intervention
versus the control group achieved PASI-75 (pooled
Table I. American College of Cardiology/American Heart Association guidelines for assessing cardiovascular
disease risk factors*
Age, y Recommendation Frequency Level of evidence
20-79 Check traditional risk factorsy Every 4-6 y IB
40-79 Estimate 10-year risk for Atherosclerotic Cardiovascular
Diseasez using Pooled Cohort Equationsx
Every 4-6 y IB
Level of evidence definitions: IA, evidence from metaanalysis of randomized controlled trials; IB, evidence from $1 randomized controlled
trial; IIA, evidence from $1 controlled study without randomization; IIB, evidence from $1 other type of experimental study; III, evidence
from nonexperimental descriptive studies, such as comparative studies, correlation studies, and case-control studies; IV, evidence from
expert committee reports or opinions or clinical experience of respected authorities, or both.
*Data from Goff et al.9
yAge, sex, total and high-density lipoprotein cholesterol, systolic blood pressure, use of antihypertensive therapy, diabetes, and current
smoking.
zDefined as nonfatal myocardial infarction, coronary heart disease death, and nonfatal and fatal stroke.
xPooled cohort equation for estimating risk takes the following variables into account: sex, race, age, treated or untreated systolic blood
pressure, total cholesterol, high-density lipoprotein cholesterol, current smoking status, and history of diabetes.
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odds ratio [OR], 2.92 [95% CI, 1.39-6.13]). Therefore,
the current data suggest that weight loss improves
psoriasis, but the clinical significance is modest.
There was at least substantial heterogeneity among
the studies included in the meta-analyses; thus,
additional studies are needed to better understand
the effects of specific weight loss interventions on
psoriasis.
Increased weight and BMI may also negatively
impact response to systemic treatments, including
biologic therapies and cyclosporine. Subanalyses of
data from RCTs have found that higher weight or BMI
is associated with poorer response to fixed-dose
biologic therapies (ie, adalimumab, etanercept, and
ustekinumab 45 mg), whereas the response to
infliximab, whose dose is weight-based, does not
vary with BMI.32,33 A US cross-sectional study of
patients with psoriasis who were seen in the routine
clinical setting supports the RCT findings.34 The
likelihood of having clear or almost clear skin as
defined by a 6-point physician global assessment
was found to decrease with increasing BMI among
psoriasis patients who were receiving adalimumab
or etanercept but not among those taking metho-
trexate. Together, these data suggest that obese
psoriasis patients may be underdosed with fixed-
dose biologics. Importantly, weight loss may
improve response to biologic therapy as suggested
by a single RCT evaluating the effect of weight
reduction by diet modification on treatment efficacy
among obese psoriasis patients who were receiving
adalimumab, etanercept, infliximab, or ustekinu-
mab.35 Another similarly designed RCT also found
an improved response to treatment with low-dose
cyclosporine among obese patients with psoriasis
randomized to a low-calorie versus normal diet.36
While weight has not been found to have an effect on
initial response to treatment with methotrexate, a
single-center study suggests that obese psoriasis
patients are more likely to experience loss of
response to methotrexate than nonobese patients.37
Lastly, obese patients with psoriasis may be at
increased risk of medication side effects from meth-
otrexate. Nonalcoholic fatty liver disease (NAFLD) is
a relative contraindication to methotrexate and is
more common among obese patients.38,39 Being
overweight may also be a risk factor for severe
hepatic fibrosis among patients with psoriasis who
are taking methotrexate.40 Therefore, it has been
recommended that obese patients with psoriasis
who are taking methotrexate undergo more aggres-
sive monitoring, including obtaining liver biopsies
both at baseline (ie, within 2-6 months of starting
therapy) and at a cumulative dose of 1.0 to 1.5 g of
methotrexate.38
Collectively, these data highlight the importance
of providing counseling to overweight and obese
patients with psoriasis about weight loss and the
impact of their weight on both psoriasis severity and
treatment response (level of evidence, IB). In addi-
tion, dermatologists should be cautious of metho-
trexate use in obese patients with psoriasis.
Hypertension
Given the association between psoriasis and hy-
pertension, patients with psoriasis should undergo at
least standard blood pressure screening that is
recommended for the general population
(Table II).41 Data suggest that psoriasis patients
with hypertension may have more severe hyperten-
sion42 and may be more likely to have poorly
controlled blood pressure than hypertensive patients
without psoriasis3; therefore, appropriate manage-
ment and monitoring of blood pressure is important
to emphasize. Lastly, as hypertension is awell-known
potential adverse effect of cyclosporine, dermatolo-
gists should use cyclosporine cautiously in patients
with psoriasis who have pre-existing hypertension.43
Diabetes
As psoriasis is associated with an increased risk of
diabetes, patients with psoriasis should be screened
for diabetes at least according to the standard
recommendations for the general population
(Table III).44-47 Based on observational data that
suggest more aggressive diabetes48 and greater
prevalence and risk of micro- and macrovascular
complications49,50 among patients with than without
psoriasis, it may be reasonable to consider more
frequent monitoring of diabetes and screening for
diabetic complications among psoriasis patients.
However, additional studies are needed to support
these initial findings and before such recommenda-
tions are implemented widely.
Dyslipidemia
More prevalent dyslipidemia among patients with
psoriasis supports lipid screening at least per stan-
dard recommendations for the general population
(Table I). Hyperlipidemia is a potential adverse effect
of treatment with acitretin51 and cyclosporine43;
therefore these medications should be used with
caution in patients with psoriasis who also have
dyslipidemia, and close lipidmonitoring is necessary.
In summary, it is essential for both clinicians and
patients to understand the possibly heightened risk
of CVD in patients with psoriasis, which may
increase with greater disease severity and longer
duration. At a minimum, screening for and manage-
ment of CV risk factors in patients with psoriasis
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should be according to the recommendations for the
general adult population (Tables I-III).6,7 Continued
basic, translational, and epidemiologic research will
be essential to support the development of evidence-
based psoriasis-specific recommendations for co-
morbid disease screening and management. In
addition, ongoing and future well-conducted RCTs
will be necessary to answer the critical question of
whether or not treatment of psoriasis itself has an
effect on CV disease, events, morbidity, and
mortality.
GASTROINTESTINAL DISEASE
Key points
d Adalimumab and infliximab are approved by
the US Food and Drug Administration for the
treatment of both psoriasis and inflamma-
tory bowel disease (Crohn’s disease and ul-
cerative colitis); ustekinumab is approved
for the treatment of both psoriasis and CD
d Secukinumab and ixekizumab should be
used with caution in patients with both
psoriasis and Crohn’s disease
d Methotrexate and acitretin should be used
cautiously in patients with psoriasis and
liver disease
d Tumor necrosis factor inhibitors should be
avoided in patients with psoriasis and mod-
erate to severe alcoholic hepatitis
Inflammatory bowel disease
It is important to understand the therapeutic
implications of comorbid inflammatory bowel
disease (IBD), which is more prevalent among
patients with than without psoriasis. Adalimumab
and infliximab are approved by the US Food and
Drug Administration (FDA) for the treatment of both
psoriasis and IBD (ie, Crohn’s disease [CD] and
ulcerative colitis [UC]), and ustekinumab was also
recently approved for the treatment of Crohn’s dis-
ease. Therefore, these biologics are the treatments of
choice in patients with both psoriasis and UC or CD.
Table II. Guidelines for hypertension screening*
Target population Screening recommendation Level of evidence
18-39 years old and blood pressure\130/85 mm Hg without any risk factorsy Screen every 3-5 y IB
Yes to any of the following:
[40 years old
At increased risk for hypertensiony
Screen annually IB
Level of evidence definitions: IA, evidence from metaanalysis of randomized controlled trials; IB, evidence from $1 randomized controlled
trial; IIA, evidence from $1 controlled study without randomization; IIB, evidence from $1 other type of experimental study; III, evidence
from nonexperimental descriptive studies, such as comparative studies, correlation studies, and case-control studies; IV, evidence from
expert committee reports or opinions or clinical experience of respected authorities, or both.
*Data from the US Preventative Services Task Force.97
yRisk factors: systolic blood pressure [130-139 mm Hg, diastolic blood pressure [85-89 mm Hg, overweight or obese, and African
American.
Table III. Guidelines for diabetes screening in asymptomatic patients*
Target population Screening recommendationy Level of evidence
Yes to both of the followingz:
40-70 years of agex
Overweight or obese (ie, body mass index $25 kg/m2)
Screen every 3 yk II-IV
Level of evidence definitions: IA, evidence from metaanalysis of randomized controlled trials; IB, evidence from $1 randomized controlled
trial; IIA, evidence from $1 controlled study without randomization; IIB, evidence from $1 other type of experimental study; III, evidence
from nonexperimental descriptive studies, such as comparative studies, correlation studies, and case-control studies; IV, evidence from
expert committee reports or opinions or clinical experience of respected authorities, or both.
*Data from the US Preventative Services Task Force.44
yScreen with any one of the following: hemoglobin A1c, fasting plasma glucose, or oral glucose tolerance test.
zPersons who have a family history of diabetes, history of gestational diabetes or polycystic ovarian syndrome, or are members of certain
racial/ethnic groups (ie, African Americans, American Indians or Alaskan Natives, Asian Americans, Hispanics or Latinos, or Native Hawaiians
or Pacific Islanders) may be at increased risk of diabetes at a younger age or at a lower body mass index and should be considered for earlier
screening.
xThe American Diabetes Association recommends screening for diabetes in adults $45 years of age and screening in persons with multiple
risk factors regardless of age.46,98
kMore frequent testing may be considered for those with abnormal tests results or those at higher risk.
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Notably, dosing of systemic medications for treat-
ment of CD and UC is often higher than that for
psoriasis. Unexpectedly, secukinumab, an IL-17A
inhibitor and biologic that was recently approved
by the FDA for the treatment of moderate to severe
psoriasis, was not only found to be ineffective for
treatment of CD but was also suggested to be
associated with higher adverse event rates than
placebo in a single clinical trial.52 Exacerbations of
CD were observed in clinical trials of secukinumab53
and ixekizumab54 for the treatment of psoriasis, and
should therefore be used with caution in patients
with both psoriasis and CD.
Hepatic disease
The greater prevalence of NAFLD among patients
with psoriasis suggests cautious use of potentially
hepatotoxic medications, such as methotrexate and
acitretin, in patients with both diseases. As discussed
previously, NAFLD is a relative contraindication to
treatment with methotrexate, and more aggressive
monitoring with liver biopsies obtained at baseline
and at a cumulative dose of 1.0 to 1.5 g of
methotrexate may be considered (level of evidence,
IV).38 Noninvasive tests to detect hepatic fibrosis,
such as various serologic tests and radiologic
imaging, such as ultrasound-based elastography,
magnetic resonance elastography, acoustic radiation
force impulse imaging, and cross-sectional imaging,
have also been suggested as promising tools but
have yet to be established in the setting of long-term
methotrexate use among patients with psoriasis.55
Moderate to severe alcoholic hepatitis is a relative
contraindication to treatment with TNF inhibitors,
specifically etanercept. In a single RCT of etanercept
in the treatment of moderate to severe alcoholic
hepatitis, higher mortality and serious infection rates
at 6 months were detected in the etanercept versus
placebo group.56 Therefore, etanercept and other
TNF inhibitors should be avoided in psoriasis
patients with moderate to severe alcoholic hepatitis
(level of evidence, IB). Importantly, patients with
psoriasis, especially those being considered for
systemic treatment with potentially hepatotoxic
medications, should be screened for alcohol use
and counseled appropriately.
CHRONIC KIDNEY DISEASE
Key point
d Patients with more severe psoriasis may
warrant closer monitoring for kidney
disease, and potentially nephrotoxic medi-
cations, such as cyclosporine, should be
used with caution
With data suggesting increased risks of chronic
kidney disease and end-stage renal disease among
patients with psoriasis,57,58 the risks versus benefits
of treating patients with moderate to severe psoriasis
with potentially nephrotoxic medications, such as
cyclosporine, should be carefully considered. Closer
monitoring for renal insufficiency with serum creat-
inine, blood urea nitrogen, and urinalysis to screen
for microalbuminuria may also be considered for
patients with psoriasis affecting $3% of their body
surface area (BSA; level of evidence, III).
MALIGNANCY
Key points
d Tumor necrosis factor inhibitors may be
associated with increased risks of nonmela-
noma skin cancer and melanoma
d Chronic oral psoralen plus ultraviolet A
phototherapy is associated with an increased
risk of nonmelanoma skin cancer, particu-
larly squamous cell carcinoma
d Patients with psoriasis on immunosuppres-
sive therapy should adhere to guidelines for
age-appropriate cancer screening
d Annual skin cancer screening may be
considered in patients with psoriasis who
are receiving immunosuppressive medica-
tions or phototherapy
The risk of malignancy among patients with
psoriasis is most convincing for lymphoma, particu-
larly cutaneous T-cell lymphoma (CTCL),59-61
although misdiagnosis of CTCL as psoriasis may at
least partially explain this association. Increased risks
of other cancers have also been suggested.62
Malignancy risk is of special concern among patients
treated with immunosuppressive systemic therapies
or phototherapy. Most studies to date have assessed
malignancy risk related to TNF inhibitors received by
patients with RA or a combination of immune-
mediated diseases (ie, RA, IBD, psoriatic diseases,
or ankylosing spondylitis) for which TNF inhibitors
are indicated. A meta-analysis of RCTs63 and
observational studies64 of patients taking TNF
inhibitors found no increased risk of internal
malignancy, but suggested that risks of nonmela-
noma skin cancer (NMSC)63,64 and melanoma64,65
may be increased. Skin cancer is also of particular
concern among patients who have received photo-
therapy. The evidence is strongest for an increased
risk of NMSC, particularly squamous cell carcinoma,
among patients treated with psoralen plus ultraviolet
A (PUVA) phototherapy whereby treatment with
[200 sessions of PUVA is associated with a 14-fold
increased risk of squamous cell carcinoma.66 The
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risk of melanoma with oral PUVA remains contro-
versial, and increased risk of skin cancer with topical
PUVA or narrowband ultraviolet B phototherapy
remains unproven.67
Especially considering the potential cancer risks
and malignancy warnings that accompany adalimu-
mab, etanercept, infliximab, and ustekinumab, it is
important that clinicians recommend and patients
adhere to age-appropriate cancer screening guide-
lines (Table IV). Screening and appropriate coun-
seling for important behavioral risk factors for cancer
(eg, smoking) is also suggested, and at least yearly
skin cancer surveillance may be considered (level of
evidence, III-IV). Importantly, malignancy, other
than NMSC, is at least a relative contraindication for
treatment with immunosuppressive therapies for
psoriasis. Guidelines for treatment of RA indicate
that treatment with biologics may be cautiously
considered in patients with history of malignancy if
they have been cancer-free for $5 years (level of
evidence, III-IV).68,69 Among psoriasis patients with
multiple NMSCs, acitretin may be considered for
both psoriasis treatment and its potential chemo-
preventive effects.70,71 Lastly, obtaining a skin biopsy
should be considered in patients with psoriasis who
have atypical lesions or disease that fails to appro-
priately respond to treatment in order to rule out
CTCL.
INFECTION
Key points
d Screening for hepatitis B and C and HIV
should be considered before starting immu-
nosuppressive therapy in patients with
psoriasis
d Screening for tuberculosis before and annu-
ally during immunosuppressive therapy in
patients with psoriasis is recommended
d Patients with psoriasis are recommended to
keepuptodatewithvaccinations, ideallybefore
receiving immunosuppressive therapies
Infection risk attributable to psoriasis itself and
immunosuppressive therapies used to treatmoderate
to severe disease remains a matter of debate.
Observational studies suggest increased risks of
serious infections,72,73 including pneumonia,74,75
among patients with psoriasis. Both a meta-analysis
of RCTs76 and an observational study77 have not
found higher risks of serious infection caused by TNF
inhibitors compared with other systemic therapies;
the effects of specific psoriasis treatments on serious
infection risk remain unclear. An observational study
of psoriasis patients suggests that the risk of herpes
zoster may be increased among patients receiving
combination biologic and methotrexate therapy.78
Considering the serious infection warnings that
accompany methotrexate, cyclosporine, adalimu-
mab, etanercept, infliximab, ustekinumab, secukinu-
mab, and ixekizumab, it is recommended that
patients with psoriasis, particularly those requiring
immunosuppressive systemic therapy, remain up to
datewith their vaccinations according to theAdvisory
Committee for Immunization Practices (level of evi-
dence, IV).79-81 As respiratory infections were found
to be the most common serious infections in patients
with psoriasis,72,73 influenza and pneumonia vacci-
nations may be particularly important. Live vaccines
should be avoided in patients who are currently
taking and are within at least 1 month of starting
immunosuppressive therapy.79
Table IV. Guidelines for age-appropriate cancer screening*
Malignancy Age, y Screen Frequency Level of evidence
Breast cancer99 50-74 Mammogram Every 2 y IA
Cervical cancer100 21-65 Papanicolaou smear Every 3 y IB
Colon cancer101 50-75 FOBT Yearly IB
Flexible sigmoidoscopy 1 FOBT Every 5 y (flexible
sigmoidoscopy);
every 3 y (FOBT)
Colonoscopy Every 10 y
Lung cancer102 55-80 with $30 pack-year
history and current smoker
or quit within 15 y
Low-dose computed tomography
scan of the chest
Yearly IA
Level of evidence definitions: IA, evidence from metaanalysis of randomized controlled trials; IB, evidence from $1 randomized controlled
trial; IIA, evidence from $1 controlled study without randomization; IIB, evidence from $1 other type of experimental study; III, evidence
from nonexperimental descriptive studies, such as comparative studies, correlation studies, and case-control studies; IV, evidence from
expert committee reports or opinions or clinical experience of respected authorities, or both.
FOBT, Fecal occult blood test.
*Refer to guideline reference documents for full screening recommendations.
J AM ACAD DERMATOL
VOLUME 76, NUMBER 3
Takeshita et al 399
Infections of special concern, especially in the
setting of treatment with immunosuppressive sys-
temic medications, include viral hepatitis B and C,
HIV, and tuberculosis (TB). The Centers for Disease
Control and Prevention (CDC) and the Medical
Board of the National Psoriasis Foundation recom-
mend screening all patients for hepatitis B infection
before initiating immunosuppressive therapy with
triple serology and baseline liver function tests.82,83
Screening for hepatitis C is more controversial, but
several guidelines recommend screening at least
high-risk populations before initiating immunosup-
pressive, particularly biologic, therapy.84-86 The CDC
also recommends $1 HIV screening test in every
person between the ages of 13 and 64.87 Finally,
considering the potential for TB reactivation, partic-
ularly with TNF inhibition, whereby the greatest risk
may be associated with adalimumab and inflixi-
mab,88,89 TB screening before starting and annually
while on biologic therapy has been recommended
(level of evidence, IV).90
MOOD DISORDERS
Key point
d Screening for mood disorders should be
considered in patients with psoriasis, partic-
ularly those with more severe disease
Reports of increased risks of depression, anxiety,
and suicidality among patients with psoriasis91,92
suggest that clinicians should consider screening
psoriasis patients for depression and suicidality,
especially if they have more severe disease.
Because both acitretin and apremilast have been
labeled with warnings for mood changes and
depression, respectively, patients who are taking
these medications should be monitored for
depression or other mood instability (level of
evidence, III).
PSORIATIC ARTHRITIS
Key points
d All patients with psoriasis should be
screened for psoriatic arthritis
d The presence of psoriatic arthritis is an
indication for systemic therapy
Psoriatic arthritis is associated with decreased
functional ability and quality of life and may result
in permanent joint damage. A diagnosis of psoriatic
arthritis is an indication for treatment with systemic
therapy. Early detection and treatment is essential to
prevent progression of this potentially debilitating
joint disease.93 All patients with psoriasis should be
asked if they have joint symptoms, including joint
swelling, tenderness, and morning stiffness that lasts
for $30 minutes and improves with activity (level of
evidence, III-IV). Diagnostic tests and treatment
recommendations are reviewed in more detail
elsewhere.94-96
In conclusion, clinicians and patients must
understand the wide range of medical comorbidities
associated with psoriasis in order to ensure
respective provision and receipt of appropriate
screening and treatment in an attempt to reduce
morbidity and mortality. Importantly, ongoing and
future well-conducted RCTs are necessary to
determine the effect of psoriasis treatment on the
associated risks of cardiometabolic, renal, malignant,
infectious, psychiatric, and other emerging comor-
bid diseases.
The authors thank Jina Chung, MD, for her early
contributions to the preparation of the manuscript.
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